Applauds Health Canada’s Approval Of Psilocybin Compassionate Access For Patients
NEW YORK, Aug. 6, 2020 — Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading psychedelic pharmaceutical company, has engaged renowned psychedelic assisted therapy expert Dr. Peter Gasser as an advisor to its LSD experiential therapy program Project Lucy.
Dr. Gasser has pioneered the legal, medical use of psychedelics through clinical research and compassionate access in Switzerland. Dr Gasser has served as the President of the Swiss Medical Society for Psycholytic Therapy since 1997. Through compassionate access in Switzerland, Dr Gasser holds several individual treatment permissions to treat patients with MDMA and LSD.
Dr. Gasser and University Hospital Basel’s Dr Matthias Liechti are conducting a Phase 2 trial of LSD assisted therapy for anxiety disorders. MindMed previously acquired the exclusive license to this ongoing Phase 2 trial through its collaboration agreement with the University Hospital Basel.
MindMed’s Project Lucy intends to start a Phase 2b human efficacy trial that will focus on experiential doses of LSD to treat anxiety disorders administered by a therapist.
“Dr. Gasser is one of the leading global experts on psychedelic assisted therapy and it’s an honor for us to work together as we build Project Lucy into a world class commercial drug development program,” said MindMed Co-Founder and Co-CEO JR Rahn. “Dr Gasser’s vast experience and history treating patients as a therapist through compassionate access in Switzerland also interests the company and will have tremendous benefits to our patients.”
Dr. Gasser helped pioneer compassionate access for end of life psychedelic assisted therapy in Switzerland. This week, the Canadian health minister approved compassionate access of psilocybin assisted therapy for terminally ill patients.
Rahn added: “Health Canada’s recognition that psychedelic substances have medicinal value and potential benefit for patients is extremely encouraging for all of us in the psychedelic inspired medical space. It takes a village of dedicated government officials, scientists, therapists and entrepreneurs to make impactful change for patients, and we hope additional clinical trials will compel regulators to further allow psychedelic inspired medicines to help the millions of patients suffering from mental health and addiction.”
About MindMed
Mind Medicine (MindMed) Inc. is a neuro-pharmaceutical company that discovers, develops and deploys psychedelic-inspired medicines to improve health, promote wellness and alleviate suffering. The company has initiated or is initiating studies to evaluate potential treatments to help patients with ADHD, anxiety, cluster headaches and substance abuse. The MindMed executive team brings extensive biopharmaceutical industry experience to this groundbreaking approach to the development of next-generation psychedelic medicines. MindMed trades on the NEO Exchange under the symbol MMED. MindMed can also be traded in the US under the symbol OTC: MMEDF and in Germany under the symbol DE:MMQ. For more information: www.mindmed.co.
MindMed Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and performance of Mind Medicine (MindMed) Inc. (“MindMed”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, MindMed’s and its collaborators’ ability to continue to conduct research and clinical programs, MindMed’s ability to manage its supply chain, product sales of products marketed by MindMed and/or its collaborators (collectively, ” Products”), and the global economy; the nature, timing, and possible success and therapeutic applications of Products and Product candidates and research and clinical programs now underway or planned; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Product candidates and new indications for Products; unforeseen safety issues resulting from the administration of Products and Product candidates in patients, including serious complications or side effects in connection with the use of MindMed’s Products and product candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict MindMed’s ability to continue to develop or commercialize Products; ongoing regulatory obligations and oversight impacting Products, research and clinical programs, and business, including those relating to patient privacy; uncertainty of market acceptance and commercial success of Products and Product candidates and the impact of studies on the commercial success of Products and Product candidates; the availability and extent of reimbursement of Products from third-party payers, including private payer healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; competing drugs and product candidates that may be superior to Products and Product candidates; the extent to which the results from the research and development programs conducted by MindMed or its collaborators may be replicated in other studies and lead to therapeutic applications; the ability of MindMed to manufacture and manage supply chains for multiple products and product candidates; the ability of MindMed’s collaborators, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labelling, distribution, and other steps related to MindMed’s Products and product candidates; unanticipated expenses; the costs of developing, producing, and selling products; the ability of MindMed to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement to be cancelled or terminated without any further product success; and risks associated with intellectual property of other parties and pending or future litigation relating thereto, other litigation and other proceedings and government investigations relating to MindMed and its operations, the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on MindMed’s business, prospects, operating results, and financial condition. Any forward-looking statements are made based on management’s current beliefs and judgment. MindMed does not undertake any obligation to update publicly any forward-looking statement.
Media Contact: Anna Walsh
E: [email protected]
P: 212-254-4730
Investor Relations: [email protected]
View original content to download multimedia:http://www.prnewswire.com/news-releases/mindmed-adds-psychedelic-assisted-therapy-expert-dr-peter-gasser-as-clinical-advisor-for-project-lucy-301107371.html
SOURCE Mind Medicine (MindMed) Inc.